Product image of Nimotop (Nimodipine) supplied by GNH India

Nimotop

Active Ingredient:
Nimodipine
Origin:
EU

Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker presented as an oral tablet for oral use. It selectively dilates cerebral vessels to prevent vasospasm, helping patients who have experienced a subarachnoid hemorrhage and reduce the risk of delayed neurological deficits.

GNH India supplies Nimotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with established quality systems and regulatory approvals across the European Union and other markets. Our distribution network ensures timely delivery and compliance with local import requirements.

Manufacturer / TM Owner

Bayer Vital Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Nimodipine is a cerebral vasodilator used to manage vascular complications after subarachnoid hemorrhage.
  • Subarachnoid hemorrhage: prevention of cerebral vasospasm.
  • Cerebral vasospasm: reduction of vessel constriction.
  • Delayed cerebral ischemia: lowering incidence after hemorrhage.
  • Neurological recovery: support of cerebral blood flow.
  • Neurovascular protection: mitigation of calcium‑mediated injury.

How It Works

  • Nimodipine acts as an L‑type calcium channel antagonist that preferentially blocks calcium influx in smooth‑muscle cells of cerebral arteries. By inhibiting these channels, it induces selective dilation of intracranial vessels, improves cerebral blood flow, and reduces the likelihood of vasospasm following subarachnoid hemorrhage. The drug’s lipophilic nature allows rapid penetration of the blood‑brain barrier, achieving therapeutic concentrations within the central nervous system while exerting minimal systemic vascular effects.

Side Effects

Nimodipine may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Headache: mild to moderate headache may occur.
  • Dizziness: sensation of light‑headedness or vertigo.
  • Nausea: occasional gastrointestinal upset.
  • Flushing: transient warmth or redness of the skin.
  • Hypotension: mild drop in blood pressure, usually asymptomatic.

Serious or Rare Side Effects

  • Severe hypotension: marked blood pressure reduction requiring medical attention.
  • Myocardial infarction: rare occurrence of heart attack.
  • Allergic reaction: rash, itching, swelling, or anaphylaxis.
  • Hepatic dysfunction: elevated liver enzymes or jaundice.
  • Neutropenia: significant reduction in white blood cells.

Precautions & Warnings

When prescribing Nimodipine, clinicians should consider several precautionary measures to ensure safe use.

  • Cardiovascular monitoring: observe blood pressure and heart rate regularly.
  • Liver function: assess hepatic enzymes before initiation and during therapy.
  • Renal impairment: adjust use in patients with severe kidney dysfunction.
  • Drug interactions: review concomitant calcium channel blockers or CYP3A4 inhibitors.
  • Pregnancy and lactation: avoid use unless benefits outweigh potential risks.
  • Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture.

Avoid Interactions

Nimodipine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors: may increase nimodipine plasma levels, risking toxicity.
  • Concurrent use with other vasodilators: can cause excessive hypotension.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inducers: may reduce therapeutic effect.
  • Antihypertensive agents: additive blood pressure lowering.
  • Beta‑blockers: may enhance bradycardia.
  • Diuretics: potential electrolyte imbalance.

Frequently Asked Questions

Nimotop contains the active ingredient nimodipine and is indicated for the prevention of cerebral vasospasm in patients who have suffered a subarachnoid hemorrhage. By reducing vessel constriction, it helps maintain adequate cerebral blood flow during the critical post‑hemorrhage period.

Nimodipine blocks L‑type calcium channels in the smooth‑muscle cells of cerebral arteries. This selective inhibition reduces calcium‑driven contraction, leading to dilation of intracranial vessels, improved cerebral perfusion, and a lower risk of vasospasm after bleeding into the subarachnoid space.

The specific dose and dosing schedule of Nimotop are determined by the prescribing clinician based on the patient’s condition, age, renal and hepatic function, and other individual factors. Typical regimens involve oral tablets taken at regular intervals, but exact details must be provided by a qualified healthcare professional.

Safety data for nimodipine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be avoided unless the potential benefit justifies the potential risk to the fetus or infant, and only under close medical supervision.

To request Nimotop, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nimodipine is more selective for cerebral vessels than many other dihydropyridine calcium channel blockers such as nicardipine or amlodipine, which affect systemic vasculature more broadly. This selectivity makes nimodipine particularly useful for preventing vasospasm after subarachnoid hemorrhage while minimizing systemic blood‑pressure effects.

Nimotop tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct sunlight, and ensure they are out of reach of children.

Nimotop is supplied as oral tablets. The tablets are taken whole with a glass of water, with or without food, according to the dosing schedule prescribed by the treating physician. Swallowing the tablet whole ensures proper absorption.

Serious adverse events, although rare, include severe hypotension, myocardial infarction, allergic reactions such as anaphylaxis, hepatic dysfunction manifested by elevated liver enzymes or jaundice, and neutropenia. Patients should be monitored for these signs, and any concerning symptoms require immediate medical evaluation.

Nimotop is contraindicated in patients with known hypersensitivity to nimodipine or any excipients, those with severe hypotension, and individuals with certain cardiac conditions where further vasodilation could be harmful. Clinicians should also exercise caution in patients with significant liver or kidney impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Nimodipine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT